Multicenter phase IV.II Trial, for the administration of capecitabine simultaneous to radiotherapy for local relapse breast cancer patients with negative HER2 [human epidermal growth factor receptor-2] tumours

Trial Profile

Multicenter phase IV.II Trial, for the administration of capecitabine simultaneous to radiotherapy for local relapse breast cancer patients with negative HER2 [human epidermal growth factor receptor-2] tumours

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2009

At a glance

  • Drugs Capecitabine (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jun 2009 Planned end date changed from 1 Dec 2010 to 1 Jan 2009 as reported by ClinicalTrials.gov.
    • 30 Jun 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 12 May 2009 Trial phase changed from IV to II as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top